Ramosetron
Ramosetron is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 3A.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 1 | 7 | 7 | 17 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 2 | 3 | 2 | 1 | 8 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | 2 | 1 | 3 | 7 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | 1 | 1 | 1 | 3 |
| Neoplasms | D009369 | C80 | — | — | 1 | 1 | — | 2 | |
| Ambulatory surgical procedures | D000556 | — | — | — | 1 | — | 1 | ||
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | 1 | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 | ||
| Shivering | D012768 | — | — | — | — | 1 | 1 | ||
| Laparoscopic cholecystectomy | D017081 | — | — | — | — | 1 | 1 | ||
| Hysteroscopy | D015907 | — | — | — | — | 1 | 1 | ||
| Prostatic neoplasms | D011471 | C61 | — | — | — | — | 1 | 1 | |
| Colonic neoplasms | D003110 | C18 | — | — | — | — | 1 | 1 | |
| Low anterior resection syndrome | D000094123 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RAMOSETRON |
| INN | ramosetron |
| Description | Ramosetron is a member of indoles. |
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 132036-88-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1643895 |
| ChEBI ID | — |
| PubChem CID | 108000 |
| DrugBank | DB09290 |
| UNII ID | 7ZRO0SC54Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR3A
HTR3A
Organism
Homo sapiens
Gene name
HTR3A
Gene synonyms
5HT3R, HTR3
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 3A
Protein synonyms
5-HT-3, 5-HT3R, 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic, 5-hydroxytryptamine receptor 3, 5HT3 serotonin receptor, Serotonin receptor 3A, Serotonin-gated ion channel receptor
Uniprot ID
Mouse ortholog
Htr3a (15561)
5-hydroxytryptamine receptor 3A (Q61226)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 877 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more